Abstract 608P
Background
Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma arising from mucosal surfaces. While MMs are distinct from cutaneous melanomas (CMs) in pathogenesis, etiology and prognosis, management of both subtypes has remained largely similar, as the rarity of the disease poses a challenge to developing evidence-based clinical guidelines for MM. We performed a meta-analysis on the use of immune checkpoint inhibitors (ICIs) and targeted therapy for MM.
Methods
We searched five databases (PubMed, Cochrane, Embase, Web of Science and Google Scholar) for studies evaluating the efficacy of ICIs and targeted therapy in the treatment of locally advanced or metastatic MMs. After including only cohort and observational studies with available overall survival (OS) and progression free survival (PFS) data, the eligible studies comprised patients treated with anti-PD1, anti-CTLA4, VEGFR inhibitors or tyrosine kinase inhibitors (TKIs). For single-arm and double-arm studies that reported Kaplan-Meier curves, we digitally reconstructed individual patient data using Guyot's algorithm and calculated the OS, PFS and hazard ratios, along with the 95% confidence intervals.
Results
We included 26 studies with a total of 1911 participants. Our results show that combined anti-PD1 and anti-CTLA4 therapy had the highest 12-month OS and 12-month PFS at 0.677 (0.608,0.754) and 0.388 (0.316,0.475) respectively. This was followed by anti-PD1 therapy alone (OS: 0.602 (0.569,0.638); PFS: 0.282 (0.251,0.317)), anti-PD1 and VEGFR inhibitor combination therapy (OS: 0.506 (0.437,0.585)), TKI therapy (OS: 0.482 (0.376,0.618); PFS: 0.083 (0.037,0.187)) and anti-CTLA4 therapy alone (OS: 0.333 (0.284,0.391); PFS: 0.098 (0.059,0.165)). In the double-arm studies, anti-PD1 and anti-CTLA4 combination therapy had similar OS and PFS with anti-PD1 treatment alone (OS: HR 0.866 (0.616,1.22); PFS: HR 0.848 (0.666,1.08)), however, anti-PD1 therapy alone had significantly better PFS than anti-CTLA4 alone (HR 0.548 (0.376,0.799)).
Conclusions
Collectively, these results demonstrate that anti-PD1 and anti-CTLA4 combination therapy has the most favorable outcome in the treatment of MM, while anti-PD1 therapy is the single best agent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract